225 related articles for article (PubMed ID: 15563850)
21. Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer.
Sawada S; Sato K; Kusuhara M; Ayaori M; Yonemura A; Tamaki K; Hiraide H; Mochizuki H; Ohsuzu F
Acta Oncol; 2005; 44(2):134-41. PubMed ID: 15788292
[TBL] [Abstract][Full Text] [Related]
22. Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial.
Chalas E; Costantino JP; Wickerham DL; Wolmark N; Lewis GC; Bergman C; Runowicz CD
Am J Obstet Gynecol; 2005 Apr; 192(4):1230-7; discussion 1237-9. PubMed ID: 15846210
[TBL] [Abstract][Full Text] [Related]
23. Myxoid leiomyosarcoma of the uterus in a patient receiving tamoxifen therapy: a case report.
Botsis D; Koliopoulos C; Kondi-Pafitis A; Creatsas G
Int J Gynecol Pathol; 2006 Apr; 25(2):173-5. PubMed ID: 16633068
[TBL] [Abstract][Full Text] [Related]
24. Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen.
Kesim MD; Aydin Y; Atis A; Mandiraci G
Climacteric; 2008 Jun; 11(3):252-7. PubMed ID: 18568790
[TBL] [Abstract][Full Text] [Related]
25. A clinicopathologic study on patients with endometrial cancer after adjuvant tamoxifen treatment for breast cancer: a single center experience.
Ravazoula P; Androutsopoulos G; Zyli P; Michail G; Kardamakis DM; Kourounis G
Breast J; 2006; 12(6):578-84. PubMed ID: 17238994
[No Abstract] [Full Text] [Related]
26. Translating trial data into patients benefits: making the right choice.
Chlebowski RT
Breast; 2008 Apr; 17 Suppl 3():S9-15. PubMed ID: 18367397
[TBL] [Abstract][Full Text] [Related]
27. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status.
Vehmanen L; Elomaa I; Blomqvist C; Saarto T
J Clin Oncol; 2006 Feb; 24(4):675-80. PubMed ID: 16446340
[TBL] [Abstract][Full Text] [Related]
28. Ovarian cysts in tamoxifen-treated women with breast cancer.
Inal MM; Incebiyik A; Sanci M; Yildirim Y; Polat M; Pilanci B; Nayki C; Camuzcuoğlu H
Eur J Obstet Gynecol Reprod Biol; 2005 May; 120(1):104-6. PubMed ID: 15866095
[TBL] [Abstract][Full Text] [Related]
29. Co-occurrence of atypical endometriosis, subserous uterine leiomyomata, sactosalpinx, serous cystadenoma and bilateral hemorrhagic corpora lutea in a perimenopausal adipose patient taking tamoxifen (20 mg/day) for invasive lobular breast cancer.
Ebert AD; Rosenow G; David M; Mechsner S; Magalov IS; Papadopoulos T
Gynecol Obstet Invest; 2008; 66(3):209-13. PubMed ID: 18645252
[TBL] [Abstract][Full Text] [Related]
30. Tamoxifen use and endometrial lesions: hysteroscopic, histological, and immunohistochemical findings in postmenopausal women with breast cancer.
Dibi RP; Zettler CG; Pessini SA; Ayub AV; de Almeida SB; da Silveira GP
Menopause; 2009; 16(2):293-300. PubMed ID: 19034048
[TBL] [Abstract][Full Text] [Related]
31. Acceptance of tamoxifen chemoprevention by physicians and women at risk.
McKay A; Latosinsky S; Martin W
Cancer; 2005 Jan; 103(1):209-10. PubMed ID: 15540238
[No Abstract] [Full Text] [Related]
32. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
33. Breast cancer and related pregnancy: suggested management according to stages of the disease and gestational stages.
Rosner D; Yeh J
J Med; 2002; 33(1-4):23-62. PubMed ID: 12939104
[TBL] [Abstract][Full Text] [Related]
34. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors.
Bober SL; Hoke LA; Duda RB; Regan MM; Tung NM
J Clin Oncol; 2004 Dec; 22(24):4951-7. PubMed ID: 15598980
[TBL] [Abstract][Full Text] [Related]
35. Hormonal treatment duration in elderly patients: an open question.
Crivellari D; Goldhirsch A; Coates A
J Clin Oncol; 2004 Mar; 22(6):1164-5; author reply 1165. PubMed ID: 15020626
[No Abstract] [Full Text] [Related]
36. Tamoxifen or raloxifene in postmenopausal women for prevention of breast cancer: a tale of two choices--counterpoint.
Fabian C
Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2210-2. PubMed ID: 18006909
[No Abstract] [Full Text] [Related]
37. Tamoxifen in breast cancer: not so easy to write off.
Munshi A; Singh P
Breast; 2008 Apr; 17(2):121-4. PubMed ID: 17923407
[TBL] [Abstract][Full Text] [Related]
38. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
[TBL] [Abstract][Full Text] [Related]
39. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Carpenter R
Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
[TBL] [Abstract][Full Text] [Related]
40. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]